feed,title,long_url,short_url
Benzinga,Caribou Biosciences Eyes $100M NASDAQ Debut To Propel Off-The-Shelf CAR-T Therapies In Blood Cancer,https://benzinga.com/general/biotech/21/07/21830111/caribou-biosciences-eyes-100m-nasdaq-debut-to-propel-off-the-shelf-car-t-therapies-in-blood-cance,https://j.mp/36be2at
